Dyne Therapeutics financials
$16.21−0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$468.2M | -$343.9M | -$242.2M | -$171.0M | -$150.0M | -$58.6M |
| Net income | -$446.2M | -$317.4M | -$235.9M | -$168.1M | -$149.3M | -$59.4M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 | $-4.13 |
| EBITDA | -$466.1M | -$342.2M | -$240.5M | -$169.3M | -$148.9M | -$57.9M |
| Operating cash flow | -$403.2M | -$292.4M | -$188.2M | -$153.6M | -$119.6M | -$46.5M |
| Free cash flow | -$423.9M | -$294.7M | -$188.9M | -$156.7M | -$123.2M | -$47.7M |
| Diluted shares | 128.4M | 94.1M | 59.7M | 52.0M | 50.9M | 14.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $893.4M | $435.4M | $121.6M | $172.1M | $200.8M | $300.9M |
| Short-term investments | $217.2M | $206.8M | $1.5M | $83.9M | $175.7M | $44.5M |
| Total debt | $148.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.19B | $691.2M | $165.1M | $306.3M | $425.7M | $353.3M |
| Total liabilities | $214.8M | $61.4M | $73.8M | $54.0M | $57.5M | $11.0M |
| Shareholders' equity | $972.1M | $629.8M | $91.3M | $252.4M | $368.2M | $342.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology